Andres Y. Maldonado
Stock Analyst at H.C. Wainwright
(4.94)
# 153
Out of 4,613 analysts
315
Total ratings
57.5%
Success rate
42.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andres Y. Maldonado
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Reiterated: Buy | $18 | $6.74 | +167.06% | 9 | Aug 7, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Rated: Buy | $40 → $35 | $10.17 | +244.15% | 18 | Aug 7, 2026 | |
| RLMD Relmada Therapeutics | Reiterated: Buy | $12 | $4.94 | +142.91% | 3 | Aug 7, 2026 | |
| SRRK Scholar Rock Holding | Reiterated: Buy | $65 | $52.92 | +22.83% | 31 | Aug 7, 2026 | |
| ZNTL Zentalis Pharmaceuticals | Maintained: Buy | $10 | $4.22 | +136.97% | 13 | Aug 7, 2026 | |
| FHTX Foghorn Therapeutics | Reiterated: Buy | $13 | $6.07 | +114.17% | 10 | Aug 7, 2026 | |
| CGON CG Oncology | Reiterated: Buy | $100 | $75.10 | +33.16% | 27 | Aug 7, 2026 | |
| IMRX Immuneering | Initiated Coverage: Buy | $14 | $4.51 | +210.42% | 1 | Aug 6, 2026 | |
| SNDX Syndax Pharmaceuticals | Reiterated: Buy | $40 → $38 | $20.40 | +86.27% | 12 | Aug 5, 2026 | |
| IBRX ImmunityBio | Reiterated: Buy | $15 | $7.64 | +96.34% | 26 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $11.15 | +79.37% | 7 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $23 | $10.59 | +117.19% | 13 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $105 → $125 | $119.21 | +4.86% | 11 | Jul 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 | $18.41 | +8.64% | 20 | Jul 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $25.03 | +59.81% | 6 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $0.7962 | +779.18% | 10 | Jun 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $4 | $1.80 | +122.22% | 13 | Jun 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 | $25.38 | +97.01% | 11 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $1.75 | +414.29% | 12 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $7.99 | +200.38% | 8 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 | $4.12 | +555.34% | 16 | May 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $4 | $0.3971 | +907.30% | 27 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $5.66 | n/a | 11 | Nov 11, 2024 |
Verastem
Aug 7, 2026
Reiterated: Buy
Price Target: $18
Current: $6.74
Upside: +167.06%
Corbus Pharmaceuticals Holdings
Aug 7, 2026
Rated: Buy
Price Target: $40 → $35
Current: $10.17
Upside: +244.15%
Relmada Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $12
Current: $4.94
Upside: +142.91%
Scholar Rock Holding
Aug 7, 2026
Reiterated: Buy
Price Target: $65
Current: $52.92
Upside: +22.83%
Zentalis Pharmaceuticals
Aug 7, 2026
Maintained: Buy
Price Target: $10
Current: $4.22
Upside: +136.97%
Foghorn Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $13
Current: $6.07
Upside: +114.17%
CG Oncology
Aug 7, 2026
Reiterated: Buy
Price Target: $100
Current: $75.10
Upside: +33.16%
Immuneering
Aug 6, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $4.51
Upside: +210.42%
Syndax Pharmaceuticals
Aug 5, 2026
Reiterated: Buy
Price Target: $40 → $38
Current: $20.40
Upside: +86.27%
ImmunityBio
Aug 4, 2026
Reiterated: Buy
Price Target: $15
Current: $7.64
Upside: +96.34%
Aug 4, 2026
Reiterated: Buy
Price Target: $20
Current: $11.15
Upside: +79.37%
Jul 29, 2026
Maintained: Buy
Price Target: $23
Current: $10.59
Upside: +117.19%
Jul 22, 2026
Reiterated: Buy
Price Target: $105 → $125
Current: $119.21
Upside: +4.86%
Jul 14, 2026
Maintained: Buy
Price Target: $20
Current: $18.41
Upside: +8.64%
Jul 9, 2026
Reiterated: Buy
Price Target: $40
Current: $25.03
Upside: +59.81%
Jun 23, 2026
Reiterated: Buy
Price Target: $7
Current: $0.7962
Upside: +779.18%
Jun 16, 2026
Maintained: Buy
Price Target: $6 → $4
Current: $1.80
Upside: +122.22%
May 26, 2026
Maintained: Buy
Price Target: $50
Current: $25.38
Upside: +97.01%
May 26, 2026
Maintained: Buy
Price Target: $9
Current: $1.75
Upside: +414.29%
May 26, 2026
Maintained: Buy
Price Target: $24
Current: $7.99
Upside: +200.38%
May 20, 2026
Reiterated: Buy
Price Target: $27
Current: $4.12
Upside: +555.34%
Dec 19, 2025
Reiterated: Buy
Price Target: $10 → $4
Current: $0.3971
Upside: +907.30%
Nov 11, 2024
Reiterated: Buy
Price Target: $4
Current: $5.66
Upside: n/a